PE20181327A1 - Metodo para tratar o mejorar trastornos metabolicos con proteinas de union para el receptor peptidico inhibidor gastrico (gipr) en combinacion con agonistas de glp-1 - Google Patents

Metodo para tratar o mejorar trastornos metabolicos con proteinas de union para el receptor peptidico inhibidor gastrico (gipr) en combinacion con agonistas de glp-1

Info

Publication number
PE20181327A1
PE20181327A1 PE2018001184A PE2018001184A PE20181327A1 PE 20181327 A1 PE20181327 A1 PE 20181327A1 PE 2018001184 A PE2018001184 A PE 2018001184A PE 2018001184 A PE2018001184 A PE 2018001184A PE 20181327 A1 PE20181327 A1 PE 20181327A1
Authority
PE
Peru
Prior art keywords
glp
agonists
combination
binding proteins
metabolic disorders
Prior art date
Application number
PE2018001184A
Other languages
English (en)
Spanish (es)
Inventor
Junming Yie
Donghui Shi
David J Lloyd
Jinghong Wang
Jr Glenn N Sivits
Murielle M Veniant-Ellison
Renee Komorowski
Neeraj Agrawal
Darren L Bates
Brandon C P Clavette
Ian N Foltz
Shu-Yin Ho
Christopher Murawsky
Xiaoshan Min
Zhulun Wang
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of PE20181327A1 publication Critical patent/PE20181327A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2869—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against hormone receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2299/00—Coordinates from 3D structures of peptides, e.g. proteins or enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Emergency Medicine (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Child & Adolescent Psychology (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
PE2018001184A 2015-12-23 2016-12-21 Metodo para tratar o mejorar trastornos metabolicos con proteinas de union para el receptor peptidico inhibidor gastrico (gipr) en combinacion con agonistas de glp-1 PE20181327A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562387486P 2015-12-23 2015-12-23
US201662337799P 2016-05-17 2016-05-17
US201662420415P 2016-11-10 2016-11-10

Publications (1)

Publication Number Publication Date
PE20181327A1 true PE20181327A1 (es) 2018-08-20

Family

ID=57956369

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2018001184A PE20181327A1 (es) 2015-12-23 2016-12-21 Metodo para tratar o mejorar trastornos metabolicos con proteinas de union para el receptor peptidico inhibidor gastrico (gipr) en combinacion con agonistas de glp-1

Country Status (25)

Country Link
US (4) US10294303B2 (enExample)
EP (1) EP3394104A2 (enExample)
JP (4) JP6948330B2 (enExample)
KR (2) KR20250121615A (enExample)
CN (2) CN109715662B (enExample)
AU (2) AU2016378739A1 (enExample)
CA (2) CA3009650A1 (enExample)
CL (2) CL2018001695A1 (enExample)
CO (1) CO2018007582A2 (enExample)
CR (1) CR20180378A (enExample)
EA (1) EA201891323A1 (enExample)
IL (2) IL296682B2 (enExample)
MA (1) MA44154A (enExample)
MX (2) MX395677B (enExample)
MY (1) MY197023A (enExample)
NZ (1) NZ743474A (enExample)
PE (1) PE20181327A1 (enExample)
PH (1) PH12018501322A1 (enExample)
SG (1) SG11201805255TA (enExample)
TN (1) TN2018000225A1 (enExample)
TW (4) TWI734722B (enExample)
UA (1) UA127495C2 (enExample)
UY (1) UY37049A (enExample)
WO (1) WO2017112824A2 (enExample)
ZA (2) ZA201803979B (enExample)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6936221B2 (ja) 2015-11-02 2021-09-15 ファイブ プライム セラピューティクス， インコーポレイテッド Ｃｄ８０細胞外ドメインポリペプチドと、がん治療でのそれらの使用
CR20180378A (es) 2015-12-23 2018-12-06 Amgen Inc Método para tratar o mejorar trastornos metabólicos con proteínas de unión para el receptor peptídico inhibidor gástrico (gipr) en combinación con agosnistas de glp-1
MX2019003727A (es) * 2016-09-29 2019-08-05 Amgen Inc Proteinas de union a antigeno de baja viscosidad y metodos de prepararlas.
KR102781241B1 (ko) 2017-01-17 2025-03-14 암젠 인크 위 저해 펩타이드 수용체(gipr)에 대한 길항제에 접합된 glp-1 수용체 작용제를 사용하여 대사 장애를 치료 또는 개선하는 방법
MX2019013919A (es) * 2017-06-20 2020-01-21 Amgen Inc Metodo para tratar o mejorar trastornos metabolicos con proteinas de union para el receptor peptidico inhibidor gastrico (gipr) en combinacion con agonistas de glp-1.
JP7250706B2 (ja) * 2017-06-21 2023-04-03 アムジエン・インコーポレーテツド 胃抑制ペプチド受容体（ｇｉｐｒ）に対するアンタゴニスト結合タンパク質／ｇｌｐ－１受容体アゴニスト融合タンパク質を使用した代謝障害の治療又は寛解方法
FI3661562T3 (fi) * 2017-08-04 2024-12-09 Amgen Inc Cys-mab:ien konjugointimenetelmä
IL322969A (en) 2017-10-12 2025-10-01 Novo Nordisk As Semaglutide in medical therapy
CN117003874A (zh) * 2018-03-20 2023-11-07 鸿运华宁（杭州）生物医药有限公司 Gipr抗体及其与glp-1的融合蛋白质，以及其药物组合物和应用
EP3934679A1 (en) 2019-03-08 2022-01-12 Amgen Inc. Growth differentiation factor 15 combination therapy
CN112521501A (zh) * 2019-09-18 2021-03-19 鸿运华宁（杭州）生物医药有限公司 Gipr抗体及其与glp-1的融合蛋白质，以及其药物组合物和应用
CN114423475B (zh) * 2019-09-30 2024-03-26 美国安进公司 药物递送装置和用于递送药物的方法
JP2022549687A (ja) * 2019-09-30 2022-11-28 アムジエン・インコーポレーテツド 薬物送達デバイス
WO2021067655A1 (en) 2019-10-04 2021-04-08 Amgen Inc. Use of gdf15 for treating cardiometabolic syndrome and other conditions
US20220403038A1 (en) * 2019-11-07 2022-12-22 Amgen Inc. Method of treating or ameliorating cushing's syndrome using binding proteins for gastric inhibitory peptide receptor (gipr)
WO2021202013A1 (en) * 2020-03-30 2021-10-07 Crystal Bioscience Inc. Anti-gipr antibody and methods of use thereof
CA3221655A1 (en) * 2021-06-09 2022-12-15 Swiftnovo Therapeutics Inc. Therapeutics and methods for treating or ameliorating metabolic disorders
JP2025531814A (ja) 2022-09-08 2025-09-25 ジーマックス バイオファーム エルエルシー Ｇｉｐｒ抗体、ｆｇｆ２１との融合タンパク質、その医薬組成物及びその使用
CN120019167A (zh) * 2022-10-12 2025-05-16 首尔大学医院 利用gipr标记物的用于预测磺酰脲类依赖性的组合物及其预测方法
KR102679905B1 (ko) * 2022-10-12 2024-07-02 서울대학교병원 Gipr 마커를 이용한 설폰요소제 의존성 예측용 조성물 및 그 예측 방법
EP4613768A1 (en) 2022-11-02 2025-09-10 Suzhou Alphamab Co., Ltd Gipr binding protein and use thereof
WO2024209050A1 (en) 2023-04-05 2024-10-10 Antag Therapeutics Aps Gip activity modulators and orthostatic intolerance
EP4455159A1 (en) * 2023-04-25 2024-10-30 3B Pharmaceuticals GmbH Gastric inhibitory peptide receptor ligands with bio-distribution modifier
US20250163168A1 (en) 2023-11-17 2025-05-22 Pfizer Inc. Novel antibodies and antibody conjugates for the treatment of metabolic disorders
TW202539633A (zh) * 2024-02-01 2025-10-16 美商輝瑞股份有限公司 葡萄糖依賴性促胰島素多肽受體拮抗劑及其用途
WO2025199030A1 (en) 2024-03-18 2025-09-25 Amgen Inc. Glp-1 receptor agonists and their medical use
WO2025226506A1 (en) * 2024-04-23 2025-10-30 Protagonist Therapeutics, Inc. Mono- and dual-agonist compounds of human glp1r and gipr for obesity & t2dm
US20260121272A1 (en) * 2024-10-31 2026-04-30 Allegro Microsystems, Llc Multi-channel isolation transformer and gate driver structures
WO2026093993A1 (en) 2024-11-01 2026-05-07 Janssen Biotech, Inc. Methods and systems for enhanced multispecific metabolic and cellular targeting

Family Cites Families (144)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4263428A (en) 1978-03-24 1981-04-21 The Regents Of The University Of California Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
DE3374837D1 (en) 1982-02-17 1988-01-21 Ciba Geigy Ag Lipids in the aqueous phase
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
HUT35524A (en) 1983-08-02 1985-07-29 Hoechst Ag Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance
US4615885A (en) 1983-11-01 1986-10-07 Terumo Kabushiki Kaisha Pharmaceutical composition containing urokinase
US4740461A (en) 1983-12-27 1988-04-26 Genetics Institute, Inc. Vectors and methods for transformation of eucaryotic cells
US4959455A (en) 1986-07-14 1990-09-25 Genetics Institute, Inc. Primate hematopoietic growth factors IL-3 and pharmaceutical compositions
US5260203A (en) 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
WO1988001649A1 (en) 1986-09-02 1988-03-10 Genex Corporation Single polypeptide chain binding molecules
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US4912040A (en) 1986-11-14 1990-03-27 Genetics Institute, Inc. Eucaryotic expression system
US5011912A (en) 1986-12-19 1991-04-30 Immunex Corporation Hybridoma and monoclonal antibody for use in an immunoaffinity purification system
US4965195A (en) 1987-10-26 1990-10-23 Immunex Corp. Interleukin-7
US4968607A (en) 1987-11-25 1990-11-06 Immunex Corporation Interleukin-1 receptors
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
WO1990005183A1 (en) 1988-10-31 1990-05-17 Immunex Corporation Interleukin-4 receptors
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5683888A (en) 1989-07-22 1997-11-04 University Of Wales College Of Medicine Modified bioluminescent proteins and their use
US5292658A (en) 1989-12-29 1994-03-08 University Of Georgia Research Foundation, Inc. Boyd Graduate Studies Research Center Cloning and expressions of Renilla luciferase
US6713610B1 (en) 1990-01-12 2004-03-30 Raju Kucherlapati Human antibodies derived from immunized xenomice
US6673986B1 (en) 1990-01-12 2004-01-06 Abgenix, Inc. Generation of xenogeneic antibodies
ES2284161T3 (es) 1990-01-12 2007-11-01 Amgen Fremont Inc. Generacion de anticuerpos xenogenicos.
US5545618A (en) 1990-01-24 1996-08-13 Buckley; Douglas I. GLP-1 analogs useful for diabetes treatment
WO1991018982A1 (en) 1990-06-05 1991-12-12 Immunex Corporation Type ii interleukin-1 receptors
US5877397A (en) 1990-08-29 1999-03-02 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US6255458B1 (en) 1990-08-29 2001-07-03 Genpharm International High affinity human antibodies and human antibodies against digoxin
US5789650A (en) 1990-08-29 1998-08-04 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5874299A (en) 1990-08-29 1999-02-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US6300129B1 (en) 1990-08-29 2001-10-09 Genpharm International Transgenic non-human animals for producing heterologous antibodies
AU8507191A (en) 1990-08-29 1992-03-30 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
JP3126980B2 (ja) 1991-03-11 2001-01-22 ザ・ユニバーシテイ・オブ・ジヨージア・リサーチ・フアウンデーシヨン・インコーポレーテツド レニラ（ｒｅｎｉｌｌａ）ルシフェラーゼのクローニング及び発現
US6565841B1 (en) 1991-03-15 2003-05-20 Amgen, Inc. Pulmonary administration of granulocyte colony stimulating factor
WO1992022646A1 (en) 1991-06-14 1992-12-23 Dnx Corp. Production of human hemoglobin in transgenic pigs
JPH06508880A (ja) 1991-07-08 1994-10-06 ユニバーシティ　オブ　マサチューセッツ　アット　アムハースト サーモトロピック液晶セグメント化ブロックコポリマー
US5470582A (en) 1992-02-07 1995-11-28 Syntex (U.S.A.) Inc. Controlled delivery of pharmaceuticals from preformed porous polymeric microparticles
ES2301158T3 (es) 1992-07-24 2008-06-16 Amgen Fremont Inc. Produccion de anticuerpos xenogenicos.
AU694745B2 (en) 1993-09-10 1998-07-30 Trustees Of Columbia University In The City Of New York, The Uses of green fluorescent protein
WO1995021191A1 (en) 1994-02-04 1995-08-10 William Ward Bioluminescent indicator based upon the expression of a gene for a modified green-fluorescent protein
US5777079A (en) 1994-11-10 1998-07-07 The Regents Of The University Of California Modified green fluorescent proteins
EP0822830B1 (en) 1995-04-27 2008-04-02 Amgen Fremont Inc. Human anti-IL-8 antibodies, derived from immunized xenomice
US5874304A (en) 1996-01-18 1999-02-23 University Of Florida Research Foundation, Inc. Humanized green fluorescent protein genes and methods
US5804387A (en) 1996-02-01 1998-09-08 The Board Of Trustees Of The Leland Stanford Junior University FACS-optimized mutants of the green fluorescent protein (GFP)
US5876995A (en) 1996-02-06 1999-03-02 Bryan; Bruce Bioluminescent novelty items
US5925558A (en) 1996-07-16 1999-07-20 The Regents Of The University Of California Assays for protein kinases using fluorescent protein substrates
DE69739172D1 (de) 1996-08-08 2009-01-29 Amylin Pharmaceuticals Inc Regulation gastrointestinaler beweglichkeit
US5976796A (en) 1996-10-04 1999-11-02 Loma Linda University Construction and expression of renilla luciferase and green fluorescent protein fusion genes
US7091183B1 (en) 1996-12-03 2006-08-15 Boston Medical Center Corporation Specific antagonists for glucose-dependent insulinotropic polypeptide (GIP)
ATE549918T1 (de) 1996-12-03 2012-04-15 Amgen Fremont Inc Menschliche antikörper, die ausdrücklich menschliches tnf alpha binden
AU5518798A (en) 1996-12-03 1998-06-29 Trustees Of Boston University Specific antagonists for glucose-dependent insulinotropic polypeptide (gip)
WO1998026277A2 (en) 1996-12-12 1998-06-18 Prolume, Ltd. Apparatus and method for detecting and identifying infectious agents
PT1629849E (pt) 1997-01-07 2013-07-09 Amylin Pharmaceuticals Llc Composições farmacêuticas que compreendem exendinas e seus agonistas
CA2196496A1 (en) 1997-01-31 1998-07-31 Stephen William Watson Michnick Protein fragment complementation assay for the detection of protein-protein interactions
US6753165B1 (en) 1999-01-14 2004-06-22 Bolder Biotechnology, Inc. Methods for making proteins containing free cysteine residues
DK1019077T4 (da) 1997-08-08 2011-03-07 Amylin Pharmaceuticals Inc Hidtil ukendte exendinagonistforbindelser
US7157555B1 (en) 1997-08-08 2007-01-02 Amylin Pharmaceuticals, Inc. Exendin agonist compounds
US6342220B1 (en) 1997-08-25 2002-01-29 Genentech, Inc. Agonist antibodies
JP2003522721A (ja) 1997-11-14 2003-07-29 アミリン・ファーマシューティカルズ，インコーポレイテッド 新規なエキセンジンアゴニスト化合物
JP2001523688A (ja) 1997-11-14 2001-11-27 アミリン・ファーマシューティカルズ，インコーポレイテッド 新規エキセンジン・アゴニスト化合物
US7223725B1 (en) 1997-11-14 2007-05-29 Amylin Pharmaceuticals, Inc. Exendin agonist compounds
US7220721B1 (en) 1997-11-14 2007-05-22 Amylin Pharmaceuticals, Inc. Exendin agonist peptides
US6703359B1 (en) 1998-02-13 2004-03-09 Amylin Pharmaceuticals, Inc. Inotropic and diuretic effects of exendin and GLP-1
ATE366115T1 (de) 1998-02-13 2007-07-15 Amylin Pharmaceuticals Inc Inotropische und diuretische effekte von exendin und glp-1
AU765703B2 (en) 1998-03-27 2003-09-25 Bruce J. Bryan Luciferases, fluorescent proteins, nucleic acids encoding the luciferases and fluorescent proteins and the use thereof in diagnostics, high throughput screening and novelty items
AU6294899A (en) 1998-10-07 2000-04-26 Medical College Of Georgia Research Institute, Inc. Glucose-dependent insulinotropic peptide for use as an osteotropic hormone
PL205713B1 (pl) 1998-12-07 2010-05-31 Sod Conseils Rech Applic Związki stanowiące analogi GLP-1, kompozycje farmaceutyczne zawierające takie związki oraz zastosowanie tych związków
CA2358107C (en) 1998-12-22 2011-08-23 Eli Lilly And Company Shelf-stable formulation of glucagon-like peptide-1
US20030087820A1 (en) 1999-01-14 2003-05-08 Young Andrew A. Novel exendin agonist formulations and methods of administration thereof
CN101181236A (zh) 1999-01-14 2008-05-21 安米林药品公司 新型exendin激动剂制剂及其给药方法
EP1658856B1 (en) 1999-01-14 2010-03-17 Amylin Pharmaceuticals, Inc. Exendins for glucagon suppression
US20050272652A1 (en) 1999-03-29 2005-12-08 Gault Victor A Peptide analogues of GIP for treatment of diabetes, insulin resistance and obesity
DE60012721T4 (de) 1999-03-29 2010-09-09 Uutech Ltd., Coleraine Analoge des magensaft inhibierenden peptides und ihre verwendung für die behandlung von diabetes
US6506724B1 (en) 1999-06-01 2003-01-14 Amylin Pharmaceuticals, Inc. Use of exendins and agonists thereof for the treatment of gestational diabetes mellitus
US6833268B1 (en) 1999-06-10 2004-12-21 Abgenix, Inc. Transgenic animals for producing specific isotypes of human antibodies via non-cognate switch regions
US6528486B1 (en) 1999-07-12 2003-03-04 Zealand Pharma A/S Peptide agonists of GLP-1 activity
EP1246638B2 (en) 2000-01-10 2014-07-30 Amylin Pharmaceuticals, Inc. Use of exendins and agonists thereof for the treatment of hypertriglyceridemia
HUP0204281A3 (en) 2000-01-27 2007-03-28 Lilly Co Eli Process for sulubilizing glucagon-like peptide 1 (glp-1) compounds
AU5675701A (en) 2000-05-16 2001-11-26 Sanwa Kagaku Kenkyusho Co Agents for preventing or ameliorating insulin resistance and/or obesity
IL158418A0 (en) 2001-04-19 2004-05-12 Scripps Research Inst In vivo incorporation of unnatural amino acids
US20050159379A1 (en) 2001-05-18 2005-07-21 Sirna Therapeutics, Inc RNA interference mediated inhibition of gastric inhibitory polypeptide (GIP) and gastric inhibitory polypeptide receptor (GIPR) gene expression using short interfering nucleic acid (siNA)
JP4566459B2 (ja) 2001-06-07 2010-10-20 株式会社日立製作所 表示装置
WO2003055914A2 (en) * 2001-12-21 2003-07-10 7Tm Pharma A/S Modified receptors for the discovery of therapeutic ligands
CN1332711C (zh) 2002-02-20 2007-08-22 埃米球科技有限公司 施用glp－1分子的方法
EP1506777A4 (en) 2002-05-22 2007-07-18 Sanwa Kagaku Kenkyusho Co MEANS FOR PREVENTING OR REDUCING FAT SUPPORT WITH A METHYLIDENHYDRAZIDE COMPOUND AS AN ACTIVE SUBSTANCE
EP1515746A2 (en) * 2002-06-11 2005-03-23 Eisai Co. Ltd Use of compounds having gip activity for the treatment of disorders associated with abnormal loss of cells and/or for the treatment of obesity
CA2489323A1 (en) 2002-06-15 2003-12-24 Enteromed, Inc. Treatment of non-alcoholic fatty liver disease
JP2006213598A (ja) 2003-03-19 2006-08-17 Sanwa Kagaku Kenkyusho Co Ltd ピラゾロピリミジン化合物及びその用途
JP4629047B2 (ja) 2003-06-12 2011-02-09 イーライ リリー アンド カンパニー Ｇｌｐ−１アナログ複合タンパク質
EP1663295A2 (en) 2003-09-01 2006-06-07 Novo Nordisk A/S Stable formulations of peptides
US20060094652A1 (en) 2004-02-11 2006-05-04 Levy Odile E Hybrid polypeptides with selectable properties
US7456254B2 (en) 2004-04-15 2008-11-25 Alkermes, Inc. Polymer-based sustained release device
US7991890B2 (en) 2004-09-30 2011-08-02 Microsoft Corporation Game console communication with a device
AU2005298689A1 (en) 2004-10-25 2006-05-04 Cytos Biotechnology Ag Gastric inhibitory polypeptide (GIP) antigen arrays and uses thereof
PT1831252E (pt) 2004-12-22 2009-09-17 Lilly Co Eli Formulações de proteínas de fusão de análogos de glp-1
US20060275288A1 (en) 2005-01-20 2006-12-07 Grihalde Nelson D GLP-1 receptor agonist and allosteric modulator monoclonal antibodies and uses thereof
BRPI0606992A2 (pt) 2005-02-11 2009-07-28 Amylin Pharmaceuticals Inc análogo e polipeptìdeos hìbridos de gip com propriedades selecionáveis
US8263545B2 (en) 2005-02-11 2012-09-11 Amylin Pharmaceuticals, Inc. GIP analog and hybrid polypeptides with selectable properties
EP1882044A1 (en) 2005-05-11 2008-01-30 sanofi-aventis Use of a gip promoter polymorphism
WO2006125763A1 (en) 2005-05-25 2006-11-30 Novo Nordisk A/S Stabilized polypeptide formulations
WO2007028633A2 (en) * 2005-09-08 2007-03-15 Uutech Limited Treatment of diabetes related obesity
EP2004238A2 (en) 2006-03-21 2008-12-24 Amylin Pharmaceuticals, Inc. Peptide-peptidase inhibitor conjugates and methods of using same
CA2657103A1 (en) 2006-07-07 2008-01-10 The Texas A&M University System Novel belactosin derivatives as therapeutic agents/biological probes and their synthesis
EP2068910A2 (en) 2006-08-04 2009-06-17 Amylin Pharmaceuticals, Inc. Use of exendins and exendin agonists and glp-1 receptor agonists for altering lipoprotein particle size and subclass composition
US8497240B2 (en) 2006-08-17 2013-07-30 Amylin Pharmaceuticals, Llc DPP-IV resistant GIP hybrid polypeptides with selectable properties
WO2008021560A2 (en) 2006-08-17 2008-02-21 Amylin Pharmaceuticals, Inc. Dpp-iv resistant gip hybrid polypeptides with selectable properties
US20090098130A1 (en) 2007-01-05 2009-04-16 Bradshaw Curt W Glucagon-like protein-1 receptor (glp-1r) agonist compounds
MX2009008241A (es) 2007-02-15 2009-10-08 Univ Indiana Res & Tech Corp Co-agonistas de receptor de glucagon/glp-1.
EP2195034A2 (en) 2007-09-27 2010-06-16 Amylin Pharmaceuticals, Inc. Peptide-peptidase inhibitor conjugates and methods of making and using same
US20090144162A1 (en) 2007-11-29 2009-06-04 Neil Milne Transaction Security Method and Apparatus
GB0814068D0 (en) 2008-08-01 2008-09-10 Univ Ulster Active immunisation against GIP
KR20110043688A (ko) * 2008-08-07 2011-04-27 입센 파마 에스.에이.에스 포도당 의존적인 인슐린 분비 자극성 폴리펩타이드 유사체
CA2733006A1 (en) 2008-08-07 2010-02-11 Ipsen Pharma S.A.S. Analogues of glucose-dependent insulinotropic polypeptide (gip) modified at n-terminal
EA020018B1 (ru) 2008-08-07 2014-08-29 Ипсен Фарма С.А.С. Процессированные аналоги глюкозозависимого инсулинотропного полипептида
WO2010016936A1 (en) 2008-08-07 2010-02-11 Ipsen Pharma S.A.S. Pharmaceutical compositions of analogues of glucose-dependent insulinotropic polypeptide
MX2011001031A (es) 2008-08-07 2011-04-26 Ipsen Pharma Sas Analogos de polipeptidos insulinotropicos dependientes de glucosa.
WO2011014680A2 (en) 2009-07-31 2011-02-03 The Board Of Trustees Of The Leland Stanford Junior University Gastric inhibitory peptide variants and their uses
EP2528618A4 (en) 2010-01-27 2015-05-27 Univ Indiana Res & Tech Corp GLUCAGON ANTAGONISTE AND GIP AGONISTS CONJUGATES AND COMPOSITIONS FOR THE TREATMENT OF METABOLISM DISEASES AND ADIPOSITAS
CA2798273A1 (en) * 2010-05-04 2011-11-10 Merrimack Pharmaceuticals, Inc. Antibodies against epidermal growth factor receptor (egfr) and uses thereof
US9023986B2 (en) 2010-10-25 2015-05-05 Hoffmann-La Roche Inc. Glucose-dependent insulinotropic peptide analogs
WO2012088116A2 (en) 2010-12-22 2012-06-28 Indiana University Research And Technology Corporation Glucagon analogs exhibiting gip receptor activity
WO2012121302A1 (ja) 2011-03-08 2012-09-13 株式会社 三和化学研究所 分析方法
US9453062B2 (en) 2011-06-10 2016-09-27 Beijing Hanmi Pharmaceutical Co., Ltd. Glucose dependent insulinotropic polypeptide analogs, pharmaceutical compositions and use thereof
CA2880929A1 (en) 2012-09-07 2014-03-13 Sanofi Fusion proteins for treating a metabolic syndrome
WO2015022420A1 (en) 2013-08-16 2015-02-19 Medimmune Limited Gip and glp-1 receptor dual-agonists for the treatment of diabetes
WO2015081440A1 (en) 2013-12-04 2015-06-11 Innovative Targeting Solutions Inc. G-protein coupled receptor agonists and methods
CN106068127B (zh) 2013-12-13 2020-06-19 诺和诺德保健股份有限公司 蛋白质的硫醚缀合方法
HUE067414T2 (hu) * 2013-12-17 2024-10-28 Mhs Care Innovation Llc Készítmények és eljárások zsírszövet felhalmozódásának kezelésére
US10570184B2 (en) 2014-06-04 2020-02-25 Novo Nordisk A/S GLP-1/glucagon receptor co-agonists for medical use
AR104932A1 (es) 2015-06-22 2017-08-23 Lilly Co Eli Compuestos co-agonistas del glucagón y péptido-1 similar al glugacón (glp-1)
TWI622596B (zh) 2015-10-26 2018-05-01 美國禮來大藥廠 升糖素受體促效劑
CR20180378A (es) 2015-12-23 2018-12-06 Amgen Inc Método para tratar o mejorar trastornos metabólicos con proteínas de unión para el receptor peptídico inhibidor gástrico (gipr) en combinación con agosnistas de glp-1
KR102781241B1 (ko) 2017-01-17 2025-03-14 암젠 인크 위 저해 펩타이드 수용체(gipr)에 대한 길항제에 접합된 glp-1 수용체 작용제를 사용하여 대사 장애를 치료 또는 개선하는 방법
MX2019013919A (es) 2017-06-20 2020-01-21 Amgen Inc Metodo para tratar o mejorar trastornos metabolicos con proteinas de union para el receptor peptidico inhibidor gastrico (gipr) en combinacion con agonistas de glp-1.
JP7250706B2 (ja) 2017-06-21 2023-04-03 アムジエン・インコーポレーテツド 胃抑制ペプチド受容体（ｇｉｐｒ）に対するアンタゴニスト結合タンパク質／ｇｌｐ－１受容体アゴニスト融合タンパク質を使用した代謝障害の治療又は寛解方法
FI3661562T3 (fi) * 2017-08-04 2024-12-09 Amgen Inc Cys-mab:ien konjugointimenetelmä
EP3934679A1 (en) * 2019-03-08 2022-01-12 Amgen Inc. Growth differentiation factor 15 combination therapy

Also Published As

Publication number Publication date
TWI891060B (zh) 2025-07-21
NZ743474A (en) 2023-03-31
CL2020003237A1 (es) 2021-07-02
CN109715662A (zh) 2019-05-03
CL2018001695A1 (es) 2018-11-23
IL259940B (en) 2022-10-01
CR20180378A (es) 2018-12-06
TW202144430A (zh) 2021-12-01
JP2024001194A (ja) 2024-01-09
JP6948330B2 (ja) 2021-10-13
US10294303B2 (en) 2019-05-21
TWI734722B (zh) 2021-08-01
WO2017112824A3 (en) 2017-08-10
US20220025059A1 (en) 2022-01-27
JP2021193135A (ja) 2021-12-23
TW202539736A (zh) 2025-10-16
AU2024200758A1 (en) 2024-05-02
US12252540B2 (en) 2025-03-18
IL259940B2 (en) 2023-02-01
IL259940A (en) 2018-07-31
KR102844773B1 (ko) 2025-08-13
IL296682A (en) 2022-11-01
US11046774B2 (en) 2021-06-29
MX2018007859A (es) 2018-11-09
JP2025124705A (ja) 2025-08-26
TWI818277B (zh) 2023-10-11
UY37049A (es) 2017-06-30
PH12018501322A1 (en) 2019-02-18
MX395677B (es) 2025-03-25
KR20180108602A (ko) 2018-10-04
CO2018007582A2 (es) 2018-07-31
UA127495C2 (uk) 2023-09-13
ZA201803979B (en) 2021-07-28
EA201891323A1 (ru) 2019-02-28
NZ783798A (en) 2025-07-25
CA3009650A1 (en) 2017-06-29
CN109715662B (zh) 2023-07-21
TW202400655A (zh) 2024-01-01
ZA201906059B (en) 2021-07-28
TW201731878A (zh) 2017-09-16
US20190276546A1 (en) 2019-09-12
WO2017112824A2 (en) 2017-06-29
AU2016378739A1 (en) 2018-07-05
JP7686719B2 (ja) 2025-06-02
BR112018012833A2 (en) 2018-12-04
WO2017112824A8 (en) 2018-08-09
TN2018000225A1 (en) 2019-10-04
EP3394104A2 (en) 2018-10-31
US20250376529A1 (en) 2025-12-11
CA3223591A1 (en) 2017-06-29
JP2019504032A (ja) 2019-02-14
KR20250121615A (ko) 2025-08-12
MX2022011277A (es) 2022-10-07
IL296682B2 (en) 2026-02-01
IL296682B1 (en) 2025-10-01
US20170275370A1 (en) 2017-09-28
MA44154A (fr) 2018-10-31
MY197023A (en) 2023-05-22
CN117106085A (zh) 2023-11-24
SG11201805255TA (en) 2018-07-30

Similar Documents

Publication Publication Date Title
IL296682B2 (en) Method for treating or improving metabolic disorders using gastric inhibitory peptide receptor binding proteins in combination with glucagon-like peptide 1 agonists
PE20191148A1 (es) Tratamiento de la migrana refractaria
PE20161033A1 (es) Proteinas de union al antigeno gitr
PE20191131A1 (es) Anticuerpos anti antigeno 4 del linfocito t citotoxico (ctla-4) activables y sus usos
PE20180927A1 (es) Moleculas de union a lag-3 y metodos de uso de las mismas
MX2024015844A (es) Anticuerpos agonistas que se unen a cd137 humano y sus usos
CL2019001926A1 (es) Anticuerpos anti-tigit y fragmentos de unión a antígeno; composición farmacéutica que los comprende; polinenucleótido que codifica dicho anticuerpo; vector que los comprende, célula hospedera; método para producir dicho anticuerpo o fragmento de unión a antígeno del mismo; y uso en el tratamiento del cáncer. (divisional de solicitud 310-2017).
AU2018210858B2 (en) Method of treating or ameliorating metabolic disorders using GLP-1 receptor agonists conjugated to antagonists for gastric inhibitory peptide receptor (GIPR)
CO2020014727A2 (es) Anticuerpo anti proteína reguladora de señales alfa sirpαlfa
AR066164A1 (es) Proteinas humanas de union a antigenos del factor estimulante de colonias de megacariocitos-macrofagos(gm-csf)
PE20230415A1 (es) ANTICUERPOS MONOCLONALES HUMANOS DIRIGIDOS CONTRA EL CORONAVIRUS 2 DEL SINDROME RESPIRATORIO AGUDO GRAVE (SARS-CoV-2)
ES2631135T3 (es) Proteínas de unión a antígeno humanas que se unen a beta-Klotho, receptores de FGF y complejos de los mismos
PE20180120A1 (es) Proteinas de union a icos
MX351349B (es) Proteinas de union a antigeno.
MX2017005642A (es) Anticuerpos anti-angiopoyetina 2 (ang2) y metodos de uso.
PE20181326A1 (es) Anticuerpos que se unen especificamente a pd-1 y sus usos
CL2018003608A1 (es) Anticuerpo aislado o fragmento de unión a antígeno del mismo que se une específicamente interleucina-25 hjumana (il-2525); composición farmacéutica que lo comprende; uso de dicha composición farmacéutica para tratar una enfermedad o trastorno asociado con la actividad o expresión de il-25. (divisional solicitud 201700703)
AR101875A1 (es) Proteína de unión a antígenos, bi-específicos del receptor anti-cgrp / receptor pac1 y usos de las mismas
PE20141660A1 (es) PROTEINAS DE UNION A ANTIGENO DE TNF-ALFA CON UNION A FcRn INCREMENTADA
PE20181336A1 (es) Anticuerpos que se unen a interleucina 8 (il-8) y sus usos
PE20181270A1 (es) Anticuerpo que neutraliza el virus respiratorio sincitial humano
PE20161571A1 (es) Anticuerpos anti-ox40 y metodos de uso
AR096687A1 (es) Anticuerpos anti-fcrh5
PE20171654A1 (es) Composiciones y metodos usados para aumentar la respuesta inmune y en la terapia del cancer
BR112017009817A2 (pt) anticorpos anti-il-1beta e métodos de utilização